Get to know our clinical trials

Trial of elranatamab in participants with newly diagnosed multiple myeloma not suitable for transplantation

Imagen de la Dra. Paula Rodríguez Otero, especialista de Hematología
Dr. Paula Rodríguez Otero Curriculum
Specialist Haematology and Haemotherapy Department
Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED, TWO-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) DARATUMUMAB LENALIDOMIDE COMPARED TO DARATUMUMUMAB LENALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR TRANSPLANTATION. IMMUNOTHERAPY
  • Code EudraCT: 2021-000803-20
  • Protocol number: C1071006
  • Promoter: Pfizer

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION